Poly(amidoamine) dendrimer based MRI contrast agents exhibiting enhanced relaxivities derived via metal preligation techniques.

This report presents the preparation and characterization of three [Gd-C-DOTA](-1)-dendrimer assemblies by way of analysis, NMRD spectroscopy, and photon correlation spectroscopy (PCS). The metal-ligand chelates were preformed in alcohol media prior to conjugation to generation 4, 5, and 6 PAMAM dendrimers. The dendrimer-based agents were purified by Sephadex G-25 column chromatography. The combustion analysis, SE-HPLC, and UV-vis data indicated chelate to dendrimer ratios of 28:1, 61:1 and 115:1, respectively. Molar relaxivity measured at pH 7.4, 22 degrees C, and 3 T (29.6, 49.8, and 89.1 mM(-1) s(-1)) indicated the viability of conjugates as MRI contrast agents. 1/T(1) NMRD profiles were measured at 23 degrees C and indicated that at 22 MHz the 1/T(1) reached a plateau at 60, 85, and 140 mM(-1) s(-1) for the generation 4, 5, and 6 dendrimer conjugates, respectively. The PCS data showed the respective sizes of 5.2, 6.5, and 7.8 nm for G-4, 5, and 6 conjugates.

[1]  Ambika Bumb,et al.  Macromolecules, dendrimers, and nanomaterials in magnetic resonance imaging: the interplay between size, function, and pharmacokinetics. , 2010, Chemical reviews.

[2]  Panos P. Fatouros,et al.  High relaxivity trimetallic nitride (Gd3N) metallofullerene MRI contrast agents with optimized functionality. , 2010, Bioconjugate chemistry.

[3]  R. Kannan,et al.  Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications. , 2010, Drug discovery today.

[4]  K. Jacobson,et al.  PEGylated dendritic unimolecular micelles as versatile carriers for ligands of G protein-coupled receptors. , 2009, Bioconjugate chemistry.

[5]  M. Brechbiel,et al.  A new approach in the preparation of dendrimer-based bifunctional diethylenetriaminepentaacetic acid MR contrast agent derivatives. , 2009, Bioconjugate chemistry.

[6]  S. Chandra,et al.  SIMS imaging of gadolinium isotopes in tissue from Nephrogenic Systemic Fibrosis patients: Release of free Gd from magnetic resonance imaging (MRI) contrast agents , 2008 .

[7]  Hanns-Joachim Weinmann,et al.  Gadolinium‐based contrast agents and their potential role in the pathogenesis of nephrogenic systemic fibrosis: The role of excess ligand , 2008, Journal of magnetic resonance imaging : JMRI.

[8]  P. Stratta,et al.  Gadolinium-enhanced magnetic resonance imaging, renal failure and nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy. , 2008, Current medicinal chemistry.

[9]  C. Robic,et al.  Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review , 2008, BioMetals.

[10]  M. Poncz,et al.  Determinants of PF4/heparin immunogenicity. , 2007, Blood.

[11]  Charu Thakral,et al.  Long-term retention of gadolinium in tissues from nephrogenic systemic fibrosis patient after multiple gadolinium-enhanced MRI scans: case report and implications. , 2007, Contrast media & molecular imaging.

[12]  Peter Caravan,et al.  Protein binding to lanthanide(III) complexes can reduce the water exchange rate at the lanthanide. , 2007, Inorganic chemistry.

[13]  Marcelino Bernardo,et al.  A dendrimer‐based nanosized contrast agent dual‐labeled for magnetic resonance and optical fluorescence imaging to localize the sentinel lymph node in mice , 2007, Journal of magnetic resonance imaging : JMRI.

[14]  D. Tomalia,et al.  Dendrimers as multi-purpose nanodevices for oncology drug delivery and diagnostic imaging. , 2007, Biochemical Society transactions.

[15]  F. Szoka,et al.  A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas , 2006, Proceedings of the National Academy of Sciences.

[16]  Peter Caravan,et al.  Strategies for increasing the sensitivity of gadolinium based MRI contrast agents. , 2006, Chemical Society reviews.

[17]  L. Matherly,et al.  Activity of dendrimer-methotrexate conjugates on methotrexate-sensitive and -resistant cell lines. , 2006, Bioconjugate chemistry.

[18]  Thommey P. Thomas,et al.  Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. , 2005, Cancer research.

[19]  J. Fréchet,et al.  Dendrimers and dendritic polymers in drug delivery. , 2005, Drug discovery today.

[20]  Steven J Wang,et al.  Characteristics of a New MRI Contrast Agent Prepared From Polypropyleneimine Dendrimers, Generation 2 , 2003, Investigative radiology.

[21]  M. Brechbiel,et al.  Dendrimer-based Macromolecular MRI Contrast Agents: Characteristics and Application , 2003, Molecular imaging.

[22]  M. Brechbiel,et al.  Pharmacokinetics and enhancement patterns of macromolecular MR contrast agents with various sizes of polyamidoamine dendrimer cores , 2001, Magnetic resonance in medicine.

[23]  E.,et al.  Paramagnetic Metal Complexes as Water Proton Relaxation Agents for NMR Imaging : Theory and Design , 2001 .

[24]  J A Frank,et al.  Synthesis and relaxometry of high‐generation (G = 5, 7, 9, and 10) PAMAM dendrimer‐DOTA‐gadolinium chelates , 1999, Journal of magnetic resonance imaging : JMRI.

[25]  J. Purans,et al.  Temperature and pH Dependence XAFS Study of Gd(DOTA)(-) and Gd(DTPA)(2)(-) Complexes: Solid State and Solution Structures. , 1998, Inorganic chemistry.

[26]  P. M. Henrichs,et al.  High relaxivity linear Gd(DTPA)‐polymer conjugates: The role of hydrophobic interactions , 1997, Magnetic resonance in medicine.

[27]  P. Sontum,et al.  Gadolinium(III) DO3A macrocycles and polyethylene glycol coupled to dendrimers : Effect of molecular weight on physical and biological properties of macromolecular magnetic resonance imaging contrast agents , 1997 .

[28]  R. Brasch,et al.  Effect of varying the molecular weight of the MR contrast agent Gd‐DTPA‐polylysine on blood pharmacokinetics and enhancement patterns , 1994, Journal of magnetic resonance imaging : JMRI.

[29]  P C Lauterbur,et al.  Dendrimer‐based metal chelates: A new class of magnetic resonance imaging contrast agents , 1994, Magnetic resonance in medicine.

[30]  Xiangyun Wang,et al.  A kinetic investigation of the lanthanide DOTA chelates. Stability and rates of formation and of dissociation of a macrocyclic gadolinium(III) polyaza polycarboxylic MRI contrast agent , 1992 .

[31]  William A. Goddard,et al.  Starburst Dendrimers: Molecular‐Level Control of Size, Shape, Surface Chemistry, Topology, and Flexibility from Atoms to Macroscopic Matter , 1990 .

[32]  G Deray,et al.  Renal tolerance of the paramagnetic contrast medium Gd-DOTA in patients with chronic renal failure. , 1990, American journal of nephrology.

[33]  J. Caillé,et al.  Experimental Study of DOTA‐Gadolinium Pharmacokinetics and Pharmacologic Properties , 1988, Investigative radiology.

[34]  J. Wittenberg,et al.  Gd-DOTA: characterization of a new paramagnetic complex. , 1988, Radiology.

[35]  M. Brechbiel,et al.  Gd(DOTA): An alternative to Gd(DTPA) as a T1,2 relaxation agent for NMR imaging or spectroscopy , 1986, Magnetic resonance in medicine.

[36]  J. Villafranca,et al.  Comparative study of glutamine synthetase bound lanthanide(III) ions using NMR relaxation and lanthanide(III) luminescence techniques. , 1985, Biochemistry.

[37]  S. H. Koenig,et al.  Relaxation of solvent protons by paramagnetic ions and its dependence on magnetic field and chemical environment: implications for NMR imaging. , 1985, Magnetic resonance in medicine.